These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 31164976)

  • 1. Antisense-mediated splice intervention to treat human disease: the odyssey continues.
    Pitout I; Flynn LL; Wilton SD; Fletcher S
    F1000Res; 2019; 8():. PubMed ID: 31164976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Translational development of splice-modifying antisense oligomers.
    Fletcher S; Bellgard MI; Price L; Akkari AP; Wilton SD
    Expert Opin Biol Ther; 2017 Jan; 17(1):15-30. PubMed ID: 27805416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Splice-switching antisense oligonucleotides as therapeutic drugs.
    Havens MA; Hastings ML
    Nucleic Acids Res; 2016 Aug; 44(14):6549-63. PubMed ID: 27288447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re-Engineering RNA Molecules into Therapeutic Agents.
    Egli M; Manoharan M
    Acc Chem Res; 2019 Apr; 52(4):1036-1047. PubMed ID: 30912917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Target selection for antisense oligonucleotide induced exon skipping in the dystrophin gene.
    Errington SJ; Mann CJ; Fletcher S; Wilton SD
    J Gene Med; 2003 Jun; 5(6):518-27. PubMed ID: 12797117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease.
    Sardone V; Zhou H; Muntoni F; Ferlini A; Falzarano MS
    Molecules; 2017 Apr; 22(4):. PubMed ID: 28379182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver as a target for oligonucleotide therapeutics.
    Sehgal A; Vaishnaw A; Fitzgerald K
    J Hepatol; 2013 Dec; 59(6):1354-9. PubMed ID: 23770039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opportunities and challenges for antisense oligonucleotide therapies.
    Kuijper EC; Bergsma AJ; Pijnappel WWMP; Aartsma-Rus A
    J Inherit Metab Dis; 2021 Jan; 44(1):72-87. PubMed ID: 32391605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nuclear antisense effects in cyclophilin A pre-mRNA splicing by oligonucleotides: a comparison of tricyclo-DNA with LNA.
    Ittig D; Liu S; Renneberg D; Schümperli D; Leumann CJ
    Nucleic Acids Res; 2004; 32(1):346-53. PubMed ID: 14726483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Alternative Splicing for Therapeutic Interventions.
    Centa JL; Hastings ML
    Methods Mol Biol; 2022; 2537():21-36. PubMed ID: 35895256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNA splicing manipulation: strategies to modify gene expression for a variety of therapeutic outcomes.
    Wilton SD; Fletcher S
    Curr Gene Ther; 2011 Aug; 11(4):259-75. PubMed ID: 21453280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Designing Effective Antisense Oligonucleotides for Exon Skipping.
    Shimo T; Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Precision Medicine through Antisense Oligonucleotide-Mediated Exon Skipping.
    Li D; Mastaglia FL; Fletcher S; Wilton SD
    Trends Pharmacol Sci; 2018 Nov; 39(11):982-994. PubMed ID: 30282590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RNA splicing manipulation: strategies to modify gene expression for a variety of therapeutic outcomes.
    Wilton SD; Fletcher S
    Curr Gene Ther; 2005 Oct; 5(5):467-83. PubMed ID: 16250888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct Reprogramming of Human DMD Fibroblasts into Myotubes for In Vitro Evaluation of Antisense-Mediated Exon Skipping and Exons 45-55 Skipping Accompanied by Rescue of Dystrophin Expression.
    Lee JJA; Saito T; Duddy W; Takeda S; Yokota T
    Methods Mol Biol; 2018; 1828():141-150. PubMed ID: 30171539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antisense oligonucleotides as therapeutics for malignant diseases.
    Ho PT; Parkinson DR
    Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic Potential of Tricyclo-DNA antisense oligonucleotides.
    Goyenvalle A; Leumann C; Garcia L
    J Neuromuscul Dis; 2016 May; 3(2):157-167. PubMed ID: 27854216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Towards a therapeutic inhibition of dystrophin exon 23 splicing in mdx mouse muscle induced by antisense oligoribonucleotides (splicomers): target sequence optimisation using oligonucleotide arrays.
    Graham IR; Hill VJ; Manoharan M; Inamati GB; Dickson G
    J Gene Med; 2004 Oct; 6(10):1149-58. PubMed ID: 15386737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic Approach to Developing Splice Modulating Antisense Oligonucleotides.
    Aung-Htut MT; McIntosh CS; Ham KA; Pitout IL; Flynn LL; Greer K; Fletcher S; Wilton SD
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31614438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of integrin alpha 4 activity through splice modulating antisense oligonucleotides.
    Aung-Htut MT; Comerford I; Johnsen R; Foyle K; Fletcher S; Wilton SD
    Sci Rep; 2019 Sep; 9(1):12994. PubMed ID: 31506448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.